C-Jun NH2-terminal kinase inhibitor bentamapimod prevents RANKL-mediated osteoclastogenesis and ovariectomy-induced osteoporosis

Key Points

• Bentamapimod significantly prevents osteoclastogenesis, offering a potential treatment for osteoporosis.
• Inhibiting c-jun nh2-terminal kinase pathway shows promise in reducing bone loss due to rankl.
• Experimental assays focused on the role of rankl in osteoclastogenesis and its modulation by bentamapimod.
• These findings indicate bentamapimod could be a key player in osteoporosis management.